Exagen inc. secures conditional ny state approval for new lupus and rheumatoid arthritis biomarkers and announces select preliminary 2024 financial results

New biomarkers on track for commercial launch in january 2025 preliminary financial results indicate record full-year revenue and avise ctd trailing twelve-month asp, with improvements to adjusted ebitda and cash burn carlsbad, calif., jan. 12, 2025 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing, today announced it has received conditional approval from the new york state department of health for its new systemic lupus erythematosus (sle) and rheumatoid arthritis (ra) biomarker assays, with a planned commercial launch in january 2025.
XGN Ratings Summary
XGN Quant Ranking